Posted on January 24, 2011 by Sitemaster
An article by Mohler and Pantuck, published on line last week in the Journal of Urology, provides two perspectives on the future potential of abiraterone acetate in the treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, androgens, castration-resistant, CRPC, intermittent, mechanism of action, metastatic, trials | 12 Comments »
Posted on June 16, 2009 by Sitemaster
This morning’s news reports address:
- Patterns of use of PSA and DRE testing in the USA
- The value of ADT in men receiving combined brachytherapy + EBRT
- Skeletal and cardiovascular adverse effects of ADT
- LHRH agonist treatment and effects on LHRH agonist receptors … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, DRE, LHRH agonist, mechanism of action, pattens of use, PSA | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 